about
Kinetics of plasma SPB and RAGE during mechanical ventilation in patients undergoing major vascular surgeryMyocardial repolarization dispersion and autonomic nerve activity in a canine experimental acute myocardial infarction modelIntra-QT spectral coherence as a possible noninvasive marker of sustained ventricular tachycardia.Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis.Surfactant-derived proteins as markers of alveolar membrane damage in heart failure.Non-invasive assessment of pulmonary hypertension: Doppler-echocardiography.Influence of aging and chronic heart failure on temporal dispersion of myocardial repolarization.Autonomic nervous system activity measured directly and QT interval variability in normal and pacing-induced tachycardia heart failure dogs.Power spectral analysis of heart rate variability and autonomic nervous system activity measured directly in healthy dogs and dogs with tachycardia-induced heart failure.Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure.Management of heart failure in the new era: the role of scores.Spatial QT Dispersion Predicts Nonsustained Ventricular Tachycardia and Correlates with Confined Systodiastolic Dysfunction in Hypertrophic Cardiomyopathy.Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction.Erectile dysfunction in heart failure: correlation with severity, exercise performance, comorbidities, and heart failure treatment.Indexes of temporal myocardial repolarization dispersion and sudden cardiac death in heart failure: any difference?NT-proatrial natriuretic peptide as a possible biomarker of cardiopulmonary involvement in sarcoidosis.Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis.Increased temporal dispersion of myocardial repolarization in myotonic dystrophy type 1: beyond the cardiac conduction system.Influence of L-arginine and vitamin C on the autonomic nervous system in chronic heart failure secondary to ischemic cardiomyopathy.Prognostic value of indeterminable anaerobic threshold in heart failure.Preclinical effects of healthy obesity on inappropriate left ventricular mass and systolic function.Disappearance of isocapnic buffering period during increasing work rate exercise at high altitude.Effects of pink grapefruit juice on QT variability in patients with dilated or hypertensive cardiomyopathy and in healthy subjects.Early impairment of myocardial function in young patients with beta-thalassemia major.Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation.Autonomic cardiovascular control and diastolic dysfunction in hypertensive subjects.Factors influencing heart rate variability power spectral analysis during controlled breathing in patients with chronic heart failure or hypertension and in healthy normotensive subjects.Alveolar membrane conductance decreases as BNP increases during exercise in heart failure. Rationale for BNP in the evaluation of dyspnea.Increased QT variability in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.Emotions that afflict the heart: influence of the autonomic nervous system on temporal dispersion of myocardial repolarization.Influence of cardiac-resynchronization therapy on heart rate and blood pressure variability: 1-year follow-up.Effects of carvedilol on oxygen uptake and heart rate kinetics in patients with chronic heart failure at simulated altitude.Cardiovascular mortality and chronotropic incompetence in systolic heart failure: the importance of a reappraisal of current cut-off criteria.Effects of beta-blockade on exercise performance at high altitude: a randomized, placebo-controlled trial comparing the efficacy of nebivolol versus carvedilol in healthy subjectsEffects of weather on neurally mediated syncope testsCirculating Plasma Surfactant Protein Type B as Biological Marker of Alveolar-Capillary Barrier Damage in Chronic Heart FailureSevere heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumptionSurfactant protein B and RAGE increases in the plasma during cardiopulmonary bypass: a pilot studyMultiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trialChronotropic Incompentence and Functional Capacity in Chronic Heart Failure: No Role of β-Blockers and β-Blocker Dose
P50
Q28242672-C0B46FC6-A0A6-4D22-8986-59726573D2B5Q33832733-B68A6957-1425-4331-81C2-12348052AC20Q34009272-19839CA3-9EA4-4E71-8C03-53A7D3C3728DQ34337289-7A6672F9-483E-4564-8C27-7729F0F55629Q34712791-253CA802-01E3-4196-B595-B4FC0BB282DBQ36497218-ABAAC9FB-5592-49D2-A9F4-72D1B663D15EQ36822401-930185B9-439E-4D95-9808-7C0F93434C90Q37374510-F31FE4BD-45DF-42CF-B0CF-2F9E354ECE55Q37374516-44F6C104-1944-45B3-B1FB-E8B79EE381E4Q37801830-0C656AB7-CE05-4725-B447-7ED4192116C2Q38235976-EE86245F-79DE-4C9B-8E3B-CF1D91922ECCQ40996134-3B29487B-7D81-49B0-A6B2-94919259535BQ41280127-8739D212-5640-47BB-8F77-09CD91995D37Q43293054-A8A908DC-6D73-4270-9C25-7F11D9379BB7Q43863639-8A6FA6D1-9CCB-41D0-99EF-1C207DD8F350Q44214089-7EDE35DC-9A82-45D7-AA18-E229B2F33565Q44350275-55C90751-78DD-47F1-A08F-5770046B654AQ44696807-9BF0A61A-A9A6-42A0-863A-8EA6526F9201Q44783809-495359B2-7E55-4054-9B09-65F53CD6EFBFQ45892581-F57FADFF-E79D-4235-BED3-53D8B8FE1E47Q46007167-AC1F8109-0006-4E2B-A25D-A9D88908C7CBQ46558373-8A127D9A-C5B8-4244-A236-3238173C0D9EQ46629387-7C26FAF2-9497-4D89-8B4B-7769ACDEAFF5Q46745560-CB051C50-1AE0-40A8-AA18-E4DE940DD381Q47724698-8059644E-D24F-44BD-BEF9-7F4A25163668Q47755962-F0216CC4-BD19-4E43-92CC-93F81810E7C3Q48001080-BA7B6A94-75F3-453B-A24D-3164FC9AFED0Q48719057-99A8EECA-D764-4C65-9562-BE2F2737BAFCQ48919182-1EECA72C-F784-45AA-954F-324D23FD4E26Q50878901-D8C6676B-0AE2-48F7-B234-FFB4E5EC2D71Q51254737-CCB94FB2-6145-44F2-828C-38769946AE2EQ51583929-4297D880-7C40-4FE9-85E0-E3ED4A2850AAQ54328541-B5115C51-D3EB-465A-B214-564AEA060C8BQ57098602-B93694AF-0AC2-44F0-B73C-F4EBC77AC603Q57113053-40A62500-CE5D-4155-87F6-AFBE389FF0D8Q57398746-8128B3E3-9516-4040-87D4-27F57D503B6BQ57487277-110BCFE5-2369-437F-BE90-F61CCD49D6C0Q59537498-7A3B2DC5-B750-4B76-AA0B-F3DB2A23D514Q60808096-A9311D30-3398-4B50-BD7B-1EF47A8761B0Q60808113-A51B607B-0321-477F-B208-F4731BCD9E39
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Damiano Magrì
@ast
Damiano Magrì
@en
Damiano Magrì
@es
Damiano Magrì
@nl
Damiano Magrì
@sl
type
label
Damiano Magrì
@ast
Damiano Magrì
@en
Damiano Magrì
@es
Damiano Magrì
@nl
Damiano Magrì
@sl
prefLabel
Damiano Magrì
@ast
Damiano Magrì
@en
Damiano Magrì
@es
Damiano Magrì
@nl
Damiano Magrì
@sl
P106
P1153
6603721046
P21
P31
P496
0000-0002-0614-2961